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The relationship between androgens and breast cancer is controversial. Androgens have 
complex effects on breast cancer progression and metastasis. Moreover, androgen 
receptor (AR) is expressed in approximately 70 to 90% of invasive breast carcinomas, 
which has prognostic relevance in basal-like cancers and in triple-negative breast cancers. 
Recent studies have associated the actin-binding proteins of the ezrin–radixin–moesin 
(ERM) family with metastasis in endocrine-sensitive cancers. We studied on T47D breast 
cancer cells whether androgens with different characteristics, such as testosterone (T), 
dihydrotestosterone (DHT), and dehydroepiandrosterone (DHEA) may regulate breast 
cancer cell motility and invasion through the control of actin remodeling. We demon-
strate that androgens promote migration and invasion in T47D via Moesin activation. 
We show that T and DHEA exert their actions via the AR and estrogen receptor (ER), 
while the non-aromatizable androgen – DHT – only recruits AR. We further report that 
androgen induced significant changes in actin organization with pseudopodia along with 
membrane ruffles formation, and this process is mediated by Moesin. Our work identifies 
novel mechanisms of action of androgens on breast cancer cells. Through the modula-
tion of Moesin, androgens alter the architecture of cytoskeleton in T47D breast cancer 
cell and promote cell migration and invasion. These results could help to understand 
the biological actions of androgens on breast cancer and, eventually, to develop new 
strategies for breast cancer treatment.
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inTrODUcTiOn
Breast cancer is the most commonly diagnosed cancer in women. About one out of eight women 
develop breast cancer throughout life (1). Early detection through screening programs and new 
therapeutic strategies have improved the chances to survive; however, many women still die because 
of metastasis.
Steroid hormones are the major modulators of breast cancer development and progression. 
In  particularly, androgens and androgen receptors (ARs) have complex effects on breast cancer 
progression and metastasis (2). The available information on how androgens modulate breast 
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cancer cells behavior is contradictory (3). Most reports indicate 
that androgens decrease proliferation of breast cancer cell lines 
(4). Mechanisms such as the inhibition of ERα transactivation 
activity support such effects (5). In agreement, women receiving 
androgens have a lower risk of developing breast cancer (6).
However, AR is expressed in approximately 70–90% of 
invasive breast carcinomas, which has prognostic relevance in 
basal-like cancers and in triple-negative breast cancers (7, 8). 
Moreover, AR overexpression is associated with acquisition of 
resistance to tamoxifen (9) and aromatase inhibitors (10, 11), 
which is key for cancer progression. Moreover, epidemiological 
evidence indicates variable associations between concentrations 
of testosterone (T), androstenedione, dehydroepiandrosterone 
(DHEA), or sex hormone-binding globulin with breast cancer 
risk (12, 13).
Recent work in breast cancer cells shows that signaling 
cascades linked to actin cytoskeleton remodeling, cell motility, 
and invasion are activated by androgens (14, 15). Cell migration 
is an integrated process requiring the development of a leading 
edge (at the front) and of a trailing edge (at the back). The cell’s 
front is a site of rapid actin polymerization: this pushes the 
leading front forward and leads to the formation of specialized 
membrane structures called ruffles, pseudopodia, and lamel-
lipodia, where interactions of the cell with other cells or with 
extracellular proteins are made possible (16). One of the main 
sets of controllers in this process is the ezrin–radixin–moesin 
(ERM) family of actin-binding proteins. The active forms of these 
proteins bind fibrillar actin, inducing its de-polymerization and 
its localization to the cell membrane to form sub-membrane 
complexes (17).
We studied whether androgens with different characteristics, 
such as testosterone (T), dihydrotestosterone (DHT), and DHEA 
may regulate breast cancer cell motility and invasion through the 
control of actin remodeling. We also tested if such actions are 
exerted through the modulation of the actin-binding protein, 
Moesin.
MaTerials anD MeThODs
cell cultures and Treatments
Cell Culture
Human breast carcinoma cell line T47D was obtained from 
American Type Culture Collection. T47D cells were grown in 
RPMI-1640 supplemented with 10% FBS (Gibco, Invitrogen), 
2  mM l-Glutamax (Gibco, Invitrogen), and ATB (Gibco, 
Invitrogen). Before experiments, medium were replaced for 
24  h with steroid-deprived FBS (Lonza Walkersville, Inc.), 
and whenever experiments investigated non-genomic effects, 
cells were kept in medium containing non-FBS for 8 h. Every 
time an inhibitor was used, the active treatments were done 
30  min afterward it. Control cells always received the same 
amount of ethanol (solvent for E2 or androgens, 0.01% final 
concentration).
Treatments
Testosterone, DHT, DHEA (10−9–10−7M), 17β-estradiol (E2, 
10−9M), flutamide (FLUT, 10−6M), aminoglutethimide (AG, 
10−6M), pertussis toxin (PTX, 100  ng/mL), and Rho-kinase 
inhibitor Y-27632 (RKI, 10−5M) were all purchased from Sigma-
Aldrich USA. ICI 182,780 (ICI, 10−6M) was obtained from Tocris 
Cookson, UK.
immunoblottings
After treatments, cells were collected on ice with lysis buffer 
containing 50 mM Tris–HCl, pH 7.4, 1 mM EDTA, 1% IGEPAL, 
protease inhibitor cocktail (Sigma-Aldrich, USA), and phos-
phatase inhibitor cocktail 3 (Sigma-Aldrich, USA). The con-
centration of total proteins was quantified by Pierce Micro BCA 
Assay (Thermo Fisher Scientific). Samples, containing 25 μg of 
protein, were separated on 10% SDS-PAGE gels and transferred 
to a PVDF membrane (Immobilon-P, Millipore). Antibodies 
against the following proteins were used: Moesin (sc-610402), 
Thr558-p-Moesin (sc-12895), AR (sc-816), estrogen receptor 
(ER) (sc-8005), and GAPDH (sc-59540), all purchased from 
Santa Cruz Biotechnology. Primary and secondary antibodies 
were incubated with standard technique. Immunodetection 
was accomplished with a quantitative digital imaging system 
(Quantity One; BioRad, USA). Densitometric analysis of the 
proteins bands was performed using the NIH ImageJ 1.49p 
software.
cell immunofluorescence
T47D cells were grown on coverslips and exposed to treatments. 
Cells were fixed with methanol at −20°C for 10 min. Blocking was 
performed with 3% serum for 20 min. Cells were incubated with 
Texas Red-X Phalloidin (Sigma). Nuclei were counterstained with 
4′-6-diamidino-2-phenylindole DAPI (Sigma) and mounted 
with VectaShield mounting medium (Vector Laboratories, 
Burlingame, CA, USA). Inmunofluorescencia was visualized 
using an Olympus BX41 microscope and recorded with a DP70 
Olympus digital camera. The red values of the 40 cells per condi-
tion were quantified using the NIH ImageJ 1.49p software by 
measuring 10 μM distances encompassing the extracellular area, 
the full thickness of the membrane, and the intracellular space. 
Two separate measures were taken in each cell. Each experiment 
was repeated three times.
gene silencing with rna interference
Gene silencing was performed using synthetic small interfering 
RNAs (siRNAs) targeting Moesin, ERα, and AR, purchased 
from Santa Cruz Biotechnology: sc-35955, sc-29305, sc-29204, 
respectively. All siRNAs were used at a final concentration of 
50–75  nM according to the manufacturer’s instructions. T47D 
were transfected with Lipofectamine RNAiMAX (Invitrogen, 
USA) in opti-MEM without ATB. Efficacy of gene silencing was 
checked after 24, 48, and 72 h by western analysis and found to 
be optimal from 24 h with 75 nMoL. T47D cells were treated 24 h 
after siRNA transfection. Each experiment was repeated three 
times.
cell Migration assay
Cell migration was assayed with razor scrape assays. Briefly, 
a razor blade was pressed through the confluent T47D breast 
cancer cell monolayer into the plastic plate to mark the starting 
FigUre 1 | androgens enhance T47D breast cancer cell migration and invasion. Steroid-deprived, ER/AR+ T47D cells were treated with 10−9M E2 or with 
increasing concentrations of T, DHT, and DHEA (10−9M–10−7M). (a) Cell migration was assayed with razor scrape assays. Horizontal cell migration was measured as 
the mean number of cells crossing the starting line after 48 h of each treatment. (B) Cell T47D invasion was assayed with matrigel invasion chambers; after 24 h, 
invasion index was quantified from the mean number of invading cells in the membrane. Images are representative and the bar graph show the mean ± SEM of the 
migration area and invasion index relative to control of three independent experiments (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 versus control).
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line. T47D cells were swept away on one side of that line. Cytosine 
β-d-arabinofuranoside hydrochloride (Sigma) (10 μM), a selec-
tive inhibitor of DNA synthesis which does not inhibit RNA 
synthesis, was added 1 h before the treatments. Absence of cell 
proliferation was checked in preliminary experiments with 
MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide) assay. Migration was monitored for 48 h. Every 24 h, 
fresh mediums and treatments were replaced. The migration 
area was visualized using an Olympus BX41 microscope and 
recorded with a high-resolution DP70 Olympus digital camera. 
The migration area was measurement from four different fields 
under 40× magnifications for each condition. Each experiment 
was repeated three times.
cell invasion assay
Cell invasion was assayed using the BD BioCoat Growth Factor 
Reduced (GFR) Matrigel Invasion Chamber (BD Bioscience, 
USA). In brief, after rehydrating the GFR Matrigel inserts, the test 
substance was added to the wells. An equal number of Control 
Inserts (no GFR Matrigel coating) was used. The chambers were 
FigUre 2 | androgens trigger actin cytoskeleton and cell membrane remodeling in T47D cells. T47D cells were treated with E2 (10−9M) or with increasing 
concentrations of T, DHT, or DHEA (10−9M–10−7M) for 20 min. Actin filaments were stained with phalloidin linked to Texas Red (red staining), and nuclei were 
counterstained with DAPI (blue staining). Immunofluorescence analysis reveals the dynamic modifications of actin filaments localization and the formation of 
specialized cell membrane structures. The histograms represent the quantification of fluorescence intensity across the lines of 40 cells of each group using ImageJ 
software. Images are representative and the bar graph represents the mean ± SEM of the membrane/cytosol actin fluorescent intensity ratio relative to control of 
triplicate experiments (*p ≤ 0.05, **p ≤ 0.01 versus control).
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incubated for 24 h at 37°C, 5% CO2 atmosphere. After incuba-
tion, non-invading cells were removed from the upper surface 
of the membrane using cotton swabs. Then the cells on the lower 
surface of the membrane were stained with Diff-Quick. Invading 
cells were visualized using a 60× magnification Olympus BX41 
microscope and photographed with a high-resolution DP70 
Olympus digital camera. The invasion value was quantified 
from the mean number of five different fields per condition. The 
normalized values were then used to calculate the Invasion index. 
Each experiment was repeated three times.
statistical analysis
Each experimental condition was reproduced in three independ-
ent experiments. All data are presented as mean ± SEM. Statistical 
analysis was performed using GraphPad Prism 6 (GraphPad 
Software). Statistical differences between means values were 
analyzed using one-way anova followed by Bonferroni posttest. 
Differences at p < 0.05 were considered significant.
resUlTs
androgen administration to T47D cells 
enhances cell Migration and invasion
We, first, studied whether androgen administration to T47D 
(AR+/ER+) breast cancer cells turns into modulation of cell 
migration. We used three different androgens that have physi-
ological and clinical relevance: the aromatizable androgen testos-
terone (T), the non-aromatizable testosterone metabolite, such as 
DHT, and the androgenic/estrogenic precursor, such as DHEA. 
The three androgens were tested at different concentrations 
FigUre 3 | androgen administration to T47D cells results in Moesin activation. (a–c) T47D cells were treated for different times (5, 10, 20, and 30 min) with 
10−8M T, DHT, and DHEA. (D–F) T47D cells were treated for 20 min with increasing concentrations of T, DHT, and DHEA (10−9M–10−7M), E2 was used as control. 
Whole cell extracts were resolved by SDS-PAGE, and wild-type Moesin and Thr558-phosphorylated Moesin (p-Moesin) levels were analyzed by western blot. Images 
are representative of triplicate experiments. Representative images are shown, and the bar graph show the mean ± SEM of the ratio Moesin/p-Moesin optical 
density relative to control of three independent experiments (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 versus control).
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spanning from physiological (10−9–10−7M) for 48 h. To eliminate 
effects on cell proliferation, T47D cells were treated with cytosine 
arabinoside (1-β-d-arabino-furanosyl)-cytosine hydrochloride 
(Ara-C, 10−5M), an inhibitor of DNA synthesis that prevents cell 
division, but allows RNA synthesis.
Exposure to T (10−9–10−7M) significantly increased T47D cell 
migration (Figure 1A), while with DHT and DHEA, we observed 
an increase only at higher concentrations (10−8 and 10−7M). Cell 
migration was related to the concentration of androgen provided. 
As a comparator, the extent of migration obtained with the higher 
dose of androgens was similar to that achieved with a physiologi-
cal amount of E2 (10−9M).
Then, we tested the effects of the same androgens on T47D cell 
invasion. Cells displayed a significant increase of invasive behav-
ior when exposed to 10−8M and 10−7M of all androgens, which 
correspond to the high physiological range for T and DHEA and 
around 10-fold higher than the normal concentration in adults 
for DHT (Figure 1B).
androgens induce rapid cytoskeletal 
rearrangements and the Development of 
specialized Membrane structures
To assess if the effects of androgens on breast cancer cell invasion 
are linked to modifications of the actin cytoskeleton, we stained 
actin filaments with Phalloidin-Texas Red and used fluorescence 
microscopy to visualize actin filaments. Non-treated cells 
displayed mainly longitudinally arranged actin filaments in the 
cytoplasm (Figure 2). However, when cells were exposed to T, 
DHT, and DHEA (10−9–10−7M), we observed a rapid change in 
actin organization, with a remodeling of the filaments toward the 
cell membrane edge after 20 min of treatment. Significant changes 
in actin organization with pseudopodia and membrane ruffles 
formation became visible from 10−8M for all androgens assayed 
(Figure  2). As we have shown in previous report (18, 19), E2 
10−9M was used as positive control of actin filaments remodeling.
T, DhT, and Dhea activate the actin-
regulatory Protein, Moesin, in T47D cells
To study if the modifications in actin arrangement and the paral-
lel enhancement of T47D cell motility may be linked to regula-
tion of actin-binding proteins, we analyzed if the ERM family 
member, Moesin, is functionally activated during exposure to 
androgens (20, 21).
Cell treatment with T, DHT, and DHEA turned into a rapid 
increase of Thr558 phosphorylation of Moesin (Figures  3A–C). 
Intensity of Moesin phosphorylation was related to the concen-
tration of T, DHT, and DHEA (Figures  3D–F). A significant 
increase of Moesin phosphorylation was observed from 10−8M 
FigUre 4 | Moesin is required for androgens-induced T47D cell migration. T47D cells were transfected with Moesin siRNAs 24 h before performing the 
horizontal migration assay. Breast cancer cells were scraped out of the cell culture dish with a razor blade at the beginning of the experiment and treated with 10−7M 
T, DHT, or DHEA for 48 h. Horizontal cell migration was measured as the number of cells crossing the starting line. Images are representative, and the bar graph 
shows the mean ± SEM of the migration area relative to control of three independent experiments (#p ≤ 0.05, ##p ≤ 0.01, ###p ≤ 0.001 versus each treatment with 
Scramble siRNA).
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for T and 10−7M for DHT and DHEA. Parallel experiments 
showed that physiological concentrations of E2 induce Moesin 
activation (Figures 3D–F).
Moesin is required for the androgen-
induced increase in T47D cell Migration
To corroborate whether Moesin is required for androgen-
dependent activation of T47D cell motility, we downregulate 
Moesin expression with siRNAs. Moesin silencing led to a 
significant decrease in cell migration induced by all androgens 
(Figure 4), while treatment with an inactive, scrambled RNA did 
not affect pro-migratory androgen effects (Figure 4).
androgens activate Moesin and actin 
remodeling through androgen and 
estrogen receptors
To study the signaling pathways involved in the effects of T, DHT, 
and DHEA, we used a set of pharmacological inhibitors includ-
ing: the AR antagonist FLUT, the ER antagonist ICI 182,780 (ICI), 
the aromatase inhibitor AG, the G protein inhibitor PTX, and 
the RKI.
Flutamide and AG decreased significantly Moesin phospho-
rylation induced by T, whereas ICI was less effective, suggesting 
that T acts though both AR and ER (Figure 5A). Phosphorylation 
of Moesin induced by DHT was significantly decreased by FLUT, 
but not by ICI or AG (Figure  5B). Because DHT cannot be 
aromatized to estrogen metabolites or does not directly bind ER, 
this result confirms that it can only act via AR. Moesin activation 
induced by DHEA was significantly reduced by FLUT and ICI, 
but was counteracted by AG (Figure  5C). This indicates that 
DHEA, which can be metabolized to estrogenic and androgenic 
metabolites, may act particularly through ER.
A similar pattern of pharmacological inhibition was seen 
when FLUT, ICI, or AG were used to counteract the actions of the 
three androgens on actin cytoskeleton remodeling (Figure 5D).
Pertussis toxin and PKI inhibited Moesin phosphorylation 
induced by androgens (Figures  5A–C), suggesting that a G 
protein- and ROCK-2-dependent signaling cascade is necessary. 
This is consistent with our previous reports where steroid hor-
mone receptors activate G-protein–ROCK-2-Moesin signaling in 
breast cancer and other cell models (22–25).
To corroborate this findings, we performed the same experi-
ments in MCF7, ER (+), AR (+) and in MDA-MB231, ER (−), 
AR (−). We found that FLUT, AG, and RKI, in presence of T, 
significantly decrease Moesin phosphorylation in MCF7 cells. 
On the other hand, Moesin activation by DHT was reduced 
when MCF7 were treated with FLUT, PTX, and RKI (Figure 
FigUre 5 | androgens activate Moesin and actin remodeling through androgen and estrogen receptors in T47D cells. T47D cells were treated with 
10−7M T, DHT, or DHEA for 20 min, in the presence or absence of the AR inhibitor flutamide (FLUT, 10−6M), the ER antagonist ICI 182,780 (ICI, 10−6M), the 
aromatase inhibitor aminoglutethimide (AG, 10−6M), the G protein inhibitor pertussis toxin (PTX, 100 ng/mL), and the Rho-kinase inhibitor Y-27632 (RKI, 10−5M). 
(a–c) Whole cell extracts were resolved by SDS-PAGE and wild-type Moesin, and Thr558-phosphorylated Moesin (p-Moesin) levels were analyzed by western blot. 
Images are representative of triplicate experiments. Representative images are shown, and the bar graph shows the mean ± SEM of the ratio Moesin/p-Moesin 
optical density relative to control of three independent experiments (#p ≤ 0.05 versus each treatment). (D) Actin filaments were stained with phalloidin linked to Texas 
Red (red staining), and nuclei were counterstained with DAPI (blue staining). Immunofluorescence analysis reveals the dynamic modifications of actin fibbers 
localization and the formation of specialized cell membrane structures. The box on top of the cells display the intensity of the signal throughout the sample areas 
measure (two per cell, indicated as the white line). Images are representative, and the bar graph represents the mean ± SEM of the membrane/cytosol actin 
fluorescent intensity ratio relative to control of triplicate experiments (#p ≤ 0.05 versus each treatment).
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S1 in Supplementary Material). Furthermore, DHEA activity 
was diminished by all inhibitors, suggesting that ER and AR are 
involved in Moesin activation. However, when MDA-MB231 
cells were treated with T, DHT, and DHEA, we saw no significant 
differences in the levels of phosphorylated Moesin (p-Moesin) 
(Figure S1 in Supplementary Material).
androgens stimulate cell invasion via 
Moesin activation through erα and ar
To corroborate the hypothesis that Moesin activation by androgens 
happens upon activation of either ERα or AR, we downregulated 
both receptors with siRNAs. We observed a significant decrease 
in Moesin phosphorylation when ERα was downregulated in 
FigUre 6 | androgens activation of Moesin and T47D cell invasion: relative contribution of er and ar. T47D cells were transfected with ERα, AR, and 
Scramble siRNAs 24 h before experiments were performed. (a,B) Transfected Cells were treated for 20 min with 10−7M T, DHT, or DHEA, and protein extracts were 
obtained. Western blot for total Moesin, p-Moesin, ERα, and AR were done. Images are representative of triplicate experiments. Representative images are shown, 
and the bar graph shows the mean ± SEM of the ratio Moesin/p-Moesin optical density relative to control of three independent experiments (#p ≤ 0.05, ##p ≤ 0.01 
versus each treatment with Scramble siRNA). (c) Transfected cells were treated with 10−7M T, DHT, or DHEA, and cell invasion was assayed with matrigel invasion 
chambers for 24 h. Invasion index was quantified from the mean number of invading cells in the membrane. Images are representative, and the bar graph shows the 
mean ± SEM of invasion index relative to control of three independent experiments (#p ≤ 0.05, ##p ≤ 0.01 versus each treatment with Scramble siRNA).
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cells treated with T and DHEA, but not with DHT (Figure 6A). 
On the other hand, downregulation of AR affected significantly 
Moesin activation associated with T, DHT, and DHEA treatments 
(Figure 6B).
Consistent with these results, the pro-invasive effects of T and 
DHEA were significantly decreased in cells where AR and ERα 
were downregulated (Figure  6C). Conversely, the pro-invasive 
effect of DHT in 3-dimensional matrices was significantly 
decreased in cells where AR expression was silencing (Figure 6C).
DiscUssiOn
The main finding of this study is that androgens modulate actin 
cytoskeleton rearrangement in T47D cells, thereby influencing 
cell migration and invasion. A precise regulation of actin dynam-
ics is necessary for cell migration, which is required for cancer 
spread, invasion, and metastasis (18).
Metastasis is a complex multistep process that involves protru-
sion of the leading edge of the cell, formation of adhesion com-
plexes, myosin/actin-mediated cell contraction, and the release 
of adhesions at the cell rear (26). One of the major players that 
participate in this process is the actin-binding protein Moesin. 
Moesin and its parent Radixin have been associated with high 
metastatic potential in the clinical setting. For instance, overex-
pression Moesin and Radixin are present in pancreatic cancers 
with lymph node metastases as compared with those where 
metastases are absent (27). Moesin seems also to be an important 
promoter of epithelial–mesenchymal transition (EMT) in human 
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mammary cell MCF10A, and it is highly expressed in a variety of 
human cancers and cancer cell lines (28–30). Moesin is regulated 
by many different stimuli, and steroid hormones and their recep-
tors seem to be particularly important (22, 23, 25).
Androgen receptor is expressed in approximately 70 to 90% 
of invasive breast carcinomas, which has prognostic relevance in 
basal-like cancers and in triple-negative breast cancers (7), sug-
gesting that it could have a biological relevance in the course of 
the disease. Historical reports identify androgens as hormones 
that blunt cancer cells proliferation in the breast (2, 31). But, more 
recent clinical evidence associates overexpression of AR with loss 
of sensitivity to standard endocrine adjuvant therapies (10, 32), 
hence increased cancer aggressiveness. Parallel reports show that 
AR regulates actin cytoskeleton architecture (14), E-Cadherin 
expression, EMT, and tumor metastasis in several breast cancer 
cell lines (33).
Our findings, therefore, raise the issue that androgens could 
play an important role in cell migration and invasion, processes 
that are closely related with tumor metastasis. The identification 
of signaling intermediates with pro-metastatic action regulated by 
androgens may allow development of therapies that could involve 
AR and its downstream intermediates as targets. AR inhibitors, 
in combination with other systemic agents, could be a valuable 
treatment for a large proportion of breast cancers (34).
From a clinical point of view, the major area of discussion 
is whether androgen treatments are safe for breast in women, 
particularly since androgen administration to women has gained 
momentum in the recent past to counteract decline of libido and 
wellbeing after the menopause (35).
The relationship between androgens and the breast is largely 
unclear. This is in part due to the androgens conversion to 
estrogens through the aromatase system. Some studies suggest 
that endogenous or exogenous androgens may increase the risk 
of developing breast cancer, but a vast amount of evidence seems 
to contradict this view (2, 34, 36). Indeed, women receiving 
androgens are at lower risk of developing breast cancer (6, 37), 
and the addition of androgens to tamoxifen increases efficacy to 
the treatment of advanced breast cancer (38).
Our data shows that T and DHEA exert their effects through 
both AR and ER, while DHT only recruits AR. This confirms that 
the biological systems that control breast cancer cell motility and 
invasiveness are redundantly controlled by different sex steroid 
receptors. This may be particularly relevant in breast cancer 
cells, where aromatization of androgens to estrogens is more 
pronounced compared with normal breast tissue (39).
In conclusion, our work identifies novel mechanisms of action 
of androgens on breast cancer cells. Through the modulation of 
the actin-binding protein, Moesin, androgens alter the architec-
ture of the cytoskeleton in T47D breast cancer cells and promote 
cell migration and invasion. These results help characterizing the 
biological actions of androgens on breast cancer and, eventually, 
to develop new strategies for treatment of breast cancer.
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FigUre s1 | McF7 and MDa MB231 cells were treated with 10−7M T, DhT, 
or Dhea for 20 min, in the presence or absence of the ar inhibitor 
flutamide (FlUT, 10−6M), the er antagonist ici 182,780 (ici, 10−6M), the 
aromatase inhibitor aminoglutethimide (ag, 10−6M), the g protein 
inhibitor pertussis toxin (PTX, 100 ng/ml), and the rho-kinase inhibitor 
Y-27632 (rKi, 10−5M). Whole cell extracts were resolved by SDS-PAGE and 
wild-type Moesin, and Thr558-phosphorylated Moesin (p-Moesin) levels were 
analyzed by western blot. Images are representative of triplicate experiments. 
Representative images are shown, and the bar graph shows the mean ± SEM of 
the ratio Moesin/p-Moesin optical density relative to control of three independent 
experiments (#p ≤ 0.05 versus each treatment).
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